Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.

Internal Medicine
Toru IshikawaToshiaki Yoshida

Abstract

The optimum retreatment strategy for chronic hepatitis C virus (HCV) patients who failed directly-acting antiviral agents (DAA)-based therapy is unknown. We herein report the outcomes of an HCV genotype (GT) 2a-infected patient with virologic failure following treatment with sofosbuvir plus ribavirin (SOF+RBV) who was successfully retreated with ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV).

References

Feb 4, 2012·Journal of Hepatology·Christoph SarrazinJean-Michel Pawlotsky
Mar 13, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Junko MatsuoUNKNOWN Hiroshima Hepatitis Study Group
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Aug 3, 2014·Journal of Hepatology·Erin GowerHomie Razavi
Dec 3, 2014·Antimicrobial Agents and Chemotherapy·Tami Pilot-MatiasChristine Collins
Dec 3, 2014·Antimicrobial Agents and Chemotherapy·Preethi KrishnanTami Pilot-Matias
Oct 30, 2016·Antiviral Research·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Sep 3, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hidenori ToyodaHiromitsu Kumada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.